Our investment approach
Validate first. Scale with evidence.
Our approach is designed to build evidence before major capital is scaled. Clinical insight, operational learning and commercial assessment inform a staged investment process, helping us identify where to proceed, where to adapt and where not to invest further.
- Capital
- Clinical expertise
- Technology
- Commercialisation
Pathway to adoption
- Capital
- Clinical expertise
- Technology
- Commercialisation
- Pathway to adoption
Five stages
From identification to commercialisation.
Validation itself takes time and resources. The sequence does not resolve every uncertainty before a first investment, and it does not remove risk. It sets out the questions we ask, and when we ask them.
- 01
Identify
Source innovation globally and screen technologies, devices and platforms against healthcare needs and strategic fit.
Our evaluation question
Is this an important problem and a credible solution?
- 02
Evaluate
Bring together clinical expert review, scientific assessment and market attractiveness.
Our evaluation question
Do the science, team and market merit further work?
- 03
Validate
Use appropriately governed clinical pilots, workflow assessment and outcome measurement to build evidence.
Our evaluation question
Does the evidence support the intended use and workflow?
- 04
Implement
Assess live integration, adoption and economic viability in relevant care settings.
Our evaluation question
Can adoption and economics work in practice?
- 05
Commercialise
Develop routes to regional deployment, licensing and strategic partnerships.
Our evaluation question
Is there a sustainable route to wider deployment?
Risk discipline
Four risks. A structured response.
- Technology risk
- Independent clinical review, pilots and evidence generation.
- Adoption risk
- Clinician engagement, nursing workflow assessment, usability and operational testing.
- Regulatory risk
- Specialist review of the regulatory, reimbursement and market-access pathway.
- Commercial risk
- Assessment of provider demand, payer engagement, distribution and strategic channels.
These disciplines are intended to improve decision-making. They do not eliminate investment, implementation or clinical risk.
Our value-creation thesis
How value can build.
A proposed sequence, not a record of CHP performance.
- 01
Innovation sourcing
- 02
Clinical validation
- 03
Data and evidence
- 04
Clinical adoption
- 05
Revenue growth
- 06
Enterprise value creation
- 07
Strategic exit
- 08
Reinvestment
Reinvestment returns the sequence to innovation sourcing. This describes the thesis we intend to follow; it is not a claim about realised returns, exits or performance.